Analyst Price Targets — BNTC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 24, 2025 11:16 am | Raghuram Selvaraju | H.C. Wainwright | $32.00 | $13.26 | TheFly | Benitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright |
| November 4, 2025 5:30 pm | — | H.C. Wainwright | $35.00 | $15.69 | TheFly | Benitec Biopharma price target raised to $35 from $28 at H.C. Wainwright |
| November 4, 2025 10:42 am | — | JMP Securities | $22.00 | $15.86 | TheFly | Benitec Biopharma price target raised to $22 from $20 at Citizens JMP |
| September 16, 2025 12:08 pm | Andreas Argyrides | Oppenheimer | $29.00 | $13.66 | TheFly | Benitec Biopharma price target lowered to $29 from $35 at Oppenheimer |
| October 14, 2024 8:24 am | Silvan Tuerkcan | JMP Securities | $18.00 | $10.86 | TheFly | Benitec Biopharma price target raised to $18 from $16 at JMP Securities |
| October 14, 2024 6:36 am | Silvan Tuerkcan | JMP Securities | $16.00 | $10.86 | TheFly | Benitec Biopharma price target lowered to $16 from $18 at JMP Securities |
| October 14, 2024 6:05 am | Mani Foroohar | Leerink Partners | $13.00 | $10.86 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Benitec BioPharma (BNTC) |
| September 24, 2024 7:53 am | Yasmeen Rahimi | Piper Sandler | $30.00 | $8.88 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Benitec BioPharma (BNTC) |
Latest News for BNTC
HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, is hosting an Industry Forum Breakfast and presentation on Tuesday, March 10, at the 2026 Muscular Dystrophy…
-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on…
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BNTC.
U.S. House Trading
No House trades found for BNTC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.